利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

43 条记录 (耗时 0.044 秒)

    PHARMACEUTICAL SOLID DISPERSIONS
    12.
    发明申请
    PHARMACEUTICAL SOLID DISPERSIONS 有权
    药物固体分散体

    公开(公告)号：US20130029965A1

    公开(公告)日：2013-01-31

    申请号：US13610350

    申请日：2012-09-11

    申请人： Walter C. Babcock ,  Dwayne T. Friesen ,  James A. S. Nightingale ,  Ravi M. Shanker

    发明人： Walter C. Babcock ,  Dwayne T. Friesen ,  James A. S. Nightingale ,  Ravi M. Shanker

    IPC分类号： A61K31/44 ,  A61K31/404 ,  A61P25/24 ,  A61K31/455

    CPC分类号： A61K9/1635 ,  A61K9/146 ,  A61K9/1652

    摘要： A composition comprises a solid dispersion comprising a low-solubility drug and at least one polymer. In another aspect of the invention, a composition comprises a solid dispersion comprising a low-solubility drug and a stabilizing polymer. At least a major portion of the drug in the dispersion is amorphous. The composition also includes a concentration-enhancing polymer that increases the concentration of the drug in a use environment. The stabilizing polymer has a glass transition temperature that is greater than the glass transition temperature of the concentration-enhancing polymer at a relative humidity of 50%.

    摘要翻译： 组合物包含包含低溶解度药物和至少一种聚合物的固体分散体。 在本发明的另一方面，组合物包含包含低溶解度药物和稳定化聚合物的固体分散体。 分散体中药物的至少大部分是无定形的。 组合物还包括增加使用环境中药物浓度的浓度增强聚合物。 稳定化聚合物的玻璃化转变温度大于相对湿度为50％时浓度增强聚合物的玻璃化转变温度。

    Pharmaceutical solid dispersions
    13.
    发明授权
    Pharmaceutical solid dispersions 有权
    药物固体分散体

    公开(公告)号：US08828442B2

    公开(公告)日：2014-09-09

    申请号：US13610350

    申请日：2012-09-11

    申请人： Walter C. Babcock ,  Dwayne T. Friesen ,  James A. S. Nightingale ,  Ravi M. Shanker

    发明人： Walter C. Babcock ,  Dwayne T. Friesen ,  James A. S. Nightingale ,  Ravi M. Shanker

    IPC分类号： A61K31/44 ,  A61K9/16 ,  A61K9/14

    CPC分类号： A61K9/1635 ,  A61K9/146 ,  A61K9/1652

    摘要： A composition comprises a solid dispersion comprising a low-solubility drug and at least one polymer. In another aspect of the invention, a composition comprises a solid dispersion comprising a low-solubility drug and a stabilizing polymer. At least a major portion of the drug in the dispersion is amorphous. The composition also includes a concentration-enhancing polymer that increases the concentration of the drug in a use environment. The stabilizing polymer has a glass transition temperature that is greater than the glass transition temperature of the concentration-enhancing polymer at a relative humidity of 50%.

    摘要翻译： 组合物包含包含低溶解度药物和至少一种聚合物的固体分散体。 在本发明的另一方面，组合物包含包含低溶解度药物和稳定化聚合物的固体分散体。 分散体中药物的至少大部分是无定形的。 组合物还包括增加使用环境中药物浓度的浓度增强聚合物。 稳定化聚合物的玻璃化转变温度大于相对湿度为50％时浓度增强聚合物的玻璃化转变温度。

    Pharmaceutical solid dispersions
    14.
    发明授权
    Pharmaceutical solid dispersions 有权
    药物固体分散体

    公开(公告)号：US08883209B2

    公开(公告)日：2014-11-11

    申请号：US12760393

    申请日：2010-05-25

    申请人： Walter C. Babcock ,  Dwayne T. Friesen ,  James A. S. Nightingale ,  Ravi M. Shanker

    发明人： Walter C. Babcock ,  Dwayne T. Friesen ,  James A. S. Nightingale ,  Ravi M. Shanker

    IPC分类号： A61K31/404 ,  A61K9/16 ,  A61K9/14

    CPC分类号： A61K9/1635 ,  A61K9/146 ,  A61K9/1652

    摘要： A composition comprises a solid dispersion comprising a low-solubility drug and at least one polymer. At least a major portion of the drug in the dispersion is amorphous. The polymer has a glass transition temperature of at least 100° C. measured at a relative humidity of fifty percent. Another aspect of the invention comprises the same composition except that the dispersion has a glass transition temperature of at least 50° C. at a relative humidity of fifty percent. In another aspect of the invention, a composition comprises a solid dispersion comprising a low-solubility drug and a stabilizing polymer. At least a major portion of the drug in the dispersion is amorphous. The composition also includes a concentration-enhancing polymer that increases the concentration of the drug in a use environment. The stabilizing polymer has a glass transition temperature that is greater than the glass transition temperature of the concentration-enhancing polymer at a relative humidity of 50%.

    摘要翻译： 组合物包含包含低溶解度药物和至少一种聚合物的固体分散体。 分散体中药物的至少大部分是无定形的。 聚合物的玻璃化转变温度至少为100℃，相对湿度为百分之五十。 本发明的另一方面包括相同的组成，不同之处在于分散体在50％的相对湿度下具有至少50℃的玻璃化转变温度。 在本发明的另一方面，组合物包含包含低溶解度药物和稳定化聚合物的固体分散体。 分散体中药物的至少大部分是无定形的。 组合物还包括增加使用环境中药物浓度的浓度增强聚合物。 稳定化聚合物的玻璃化转变温度大于相对湿度为50％时浓度增强聚合物的玻璃化转变温度。

    Pharmaceutical solid dispersions
    15.
    发明授权
    Pharmaceutical solid dispersions 有权
    药物固体分散体

    公开(公告)号：US08481081B2

    公开(公告)日：2013-07-09

    申请号：US10459808

    申请日：2003-06-10

    申请人： Walter C. Babcock ,  Dwayne T. Friesen ,  James A. S. Nightingale ,  Ravi M. Shanker

    发明人： Walter C. Babcock ,  Dwayne T. Friesen ,  James A. S. Nightingale ,  Ravi M. Shanker

    IPC分类号： A61K9/14

    CPC分类号： A61K9/1635 ,  A61K9/146 ,  A61K9/1652

    摘要： A composition comprises a solid dispersion comprising a low-solubility drug and at least one polymer. At least a major portion of the drug in the dispersion is amorphous. The polymer has a glass transition temperature of at least 100° C. measured at a relative humidity of fifty percent. Another aspect of the invention comprises the same composition except that the dispersion has a glass transition temperature of at least 50° C. at a relative humidity of fifty percent. In another aspect of the invention, a composition comprises a solid dispersion comprising a low-solubility drug and a stabilizing polymer. At least a major portion of the drug in the dispersion is amorphous. The composition also includes a concentration-enhancing polymer that increases the concentration of the drug in a use environment. The stabilizing polymer has a glass transition temperature that is greater than the glass transition temperature of the concentration-enhancing polymer at a relative humidity of 50%.

    摘要翻译： 组合物包含包含低溶解度药物和至少一种聚合物的固体分散体。 分散体中药物的至少大部分是无定形的。 聚合物的玻璃化转变温度至少为100℃，相对湿度为百分之五十。 本发明的另一方面包括相同的组成，不同之处在于分散体在50％的相对湿度下具有至少50℃的玻璃化转变温度。 在本发明的另一方面，组合物包含包含低溶解度药物和稳定化聚合物的固体分散体。 分散体中药物的至少大部分是无定形的。 组合物还包括增加使用环境中药物浓度的浓度增强聚合物。 稳定化聚合物的玻璃化转变温度大于相对湿度为50％时浓度增强聚合物的玻璃化转变温度。

    PHARMACEUTICAL SOLID DISPERSIONS
    19.
    发明申请
    PHARMACEUTICAL SOLID DISPERSIONS 有权
    药物固体分散体

    公开(公告)号：US20100256110A1

    公开(公告)日：2010-10-07

    申请号：US12760393

    申请日：2010-05-25

    申请人： Walter C. Babcock ,  Dwayne T. Friesen ,  James A.S. Nightingale ,  Ravi M. Shanker

    发明人： Walter C. Babcock ,  Dwayne T. Friesen ,  James A.S. Nightingale ,  Ravi M. Shanker

    IPC分类号： A61K31/404 ,  A61K31/44 ,  A61P9/12 ,  A61P7/02 ,  A61P3/10 ,  A61P35/00 ,  A61P15/10 ,  A61P29/00 ,  A61P25/18 ,  A61P31/04 ,  A61P31/10 ,  A61P25/16 ,  A61P25/28 ,  A61P31/12

    CPC分类号： A61K9/1635 ,  A61K9/146 ,  A61K9/1652

    摘要： A composition comprises a solid dispersion comprising a low-solubility drug and at least one polymer. At least a major portion of the drug in the dispersion is amorphous. The polymer has a glass transition temperature of at least 100° C. measured at a relative humidity of fifty percent. Another aspect of the invention comprises the same composition except that the dispersion has a glass transition temperature of at least 50° C. at a relative humidity of fifty percent. In another aspect of the invention, a composition comprises a solid dispersion comprising a low-solubility drug and a stabilizing polymer. At least a major portion of the drug in the dispersion is amorphous. The composition also includes a concentration-enhancing polymer that increases the concentration of the drug in a use environment. The stabilizing polymer has a glass transition temperature that is greater than the glass transition temperature of the concentration-enhancing polymer at a relative humidity of 50%.

    摘要翻译： 组合物包含包含低溶解度药物和至少一种聚合物的固体分散体。 分散体中药物的至少大部分是无定形的。 聚合物的玻璃化转变温度至少为100℃，相对湿度为百分之五十。 本发明的另一方面包括相同的组成，不同之处在于分散体在50％的相对湿度下具有至少50℃的玻璃化转变温度。 在本发明的另一方面，组合物包含包含低溶解度药物和稳定化聚合物的固体分散体。 分散体中药物的至少大部分是无定形的。 组合物还包括增加使用环境中药物浓度的浓度增强聚合物。 稳定化聚合物的玻璃化转变温度大于相对湿度为50％时浓度增强聚合物的玻璃化转变温度。